Enso Ventures

Founded in 2014, Cognitive Geology operates as a specialist software provider for the oil industry.

NeuroVia, Inc. is committed to addressing unmet medical needs in neurological diseases with the primary goal to arrest the onset of devastating neurological deficits associated with X-ALD.

UltraSoC Technologies is an independent provider of SoC infrastructure to enable rapid development of embedded systems based on advanced SoC devices. Its head office is in Cambridge and it has research and development labs in Colchester.

Cavion is a clinical stage pharmaceutical company committed to providing patients with therapies for cancer and neurologic diseases through the development of drugs that selectively inhibit the T-type calcium channel (Cav3). Built on the discovery by Cavion’s founders that ion channels are a target for the treatment of solid tumor cancers, they were the first company to invent therapies engaging Cav3 for the treatment of solid tumors. The innovative idea of treating pathologically proliferating, non-electrically excitable cells by targeting an ion channel has already shown success in preclinical studies and is being tested in Phase 1 safety and dose-finding clinical trials in brain cancer. Their technology is intended to magnify the effects of combined chemotherapy, radiation, and targeted therapies for all solid tumor cancers. Their neurology program uses superior chemistry and clinical expertise to deliver a novel class of drugs that will provide patients with treatments for neurologic diseases. While Cav3 is an established target in neurology, particularly neuropathic pain, Cavion is working to bring the first non-addictive, non-opioid T-type calcium channel antagonist to patients with neuropathic pain. Given that Cav3 plays a role in numerous pathologic conditions, Cavion is simultaneously developing therapies for additional neurologic afflictions such as essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome.

Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent small molecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, it's lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419. The company was established in 2009 and is headquartered in Malvern, Pennsylvania, United States.

Seres Therapeutics is a clinical-stage biotherapeutic company that develops ecobiotic therapeutic products. They engaged in developing biological drugs which are referred to as ecobiotic microbiome therapeutics. The company is a group of experts in microbiome research and drug development. Its executive team, board of directors, and scientific advisory board have a wealth of experience in the development, regulatory approval, and profitable commercialization of a wide range of therapeutic products.

Axcella is a clinical-stage biotechnology company that treats complex diseases using endogenous metabolic modulator (EMM) compositions. They combine biological pathways with developments in systems biology and machine learning. Their proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative, and liver conditions.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Seres Therapeutics is a clinical-stage biotherapeutic company that develops ecobiotic therapeutic products. They engaged in developing biological drugs which are referred to as ecobiotic microbiome therapeutics. The company is a group of experts in microbiome research and drug development. Its executive team, board of directors, and scientific advisory board have a wealth of experience in the development, regulatory approval, and profitable commercialization of a wide range of therapeutic products.

Snap Ring Joint Limited is a Jersey-based, non-listed engineering company, built on a solid body of experience in fittings manufacture and problem-solving expertise. Its UK-based R&D team boasts over fifty years of experience in specialist fittings. Over the last four years, it has developed and tested a range of ground-breaking pipeline coupling technologies. The global market for pipeline connections is enormous and covers many industry sectors, notably oil and gas (upstream and downstream), shipping, water (including desalination), power generation (including nuclear), chemical, mining and agriculture. The company holds an exclusive licence to the design of the Snap Ring Joint (SRJ), a revolutionary pipeline coupling system, and the intellectual property (IP) now extends to more than seventy countries worldwide. The SRJ has achieved Lloyds Register and ABS Type Approval for hydrocarbons service. Pipes and hoses are manufactured in a range of materials and are available in an almost infinite number of sizes. The SRJ is suitable for a wide variety of applications and for virtually all industries that use pipe connections.

Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignant cells. Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin.

Cambridge Nanotherm manufacturers radically cooler and LEDs. They creates thermal management technology for LED applications and electronics and a thin ceramic layer on the surface of aluminium to form a nano-ceramic dielectric with thermal conductivity.

Super-property nanomaterials for metal plating, durable low friction coatings, and thermal and mechanical polymer applications. "Hard as hell, but cooler" Carbodeon supplies superhard materials for applications where toughness is at a premium. Our nanodiamond products each possess the desired properties fine-tuned for a growing number of dedicated applications. These grades are sold under the name uDiamond:registered:. Similarly, our Nicanite:registered: graphitic carbon nitride can be converted to carbon nitride film coatings with unique properties.